Port site metastasis after laparoscopic-assisted distal gastrectomy (LADG).
This report describes a case of port site metastasis after laparoscopic gastrectomy for gastric cancer. A 57-year-old man with clinical cTNM stage II (T2 N0 M0) gastric cancer was admitted to our hospital. After administration of an oral fluoropyrimidine drug (S-1) for 2 weeks, he underwent laparoscopy-assisted distal gastrectomy (LADG). On hematoxylin and eosin staining, the pTNM stage was IA (T1b N0 M0). Eighteen months later, the patient developed a subcutaneous metastasis at the trocar site. A second operation was performed, and the abdominal wall mass was resected. The histological finding confirmed a diagnosis of metastatic gastric carcinoma. Immunohistochemical analysis revealed micrometastasis in fat tissue adjacent to the lymph node near the left gastric artery. Surgeons should be aware that port site metastasis can occur in patients undergoing LADG for gastric cancer with lymphatic micrometastasis, which is undetectable on routine hematoxylin and eosin staining.
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Katsunobu
K
Sakurai
Hiroaki
H
Tanaka
Tomohiro
T
Lee
Kazuya
K
Muguruma
Naoshi
N
Kubo
Masakazu
M
Yashiro
Masaichi
M
Ohira
Kosei
K
Hirakawa
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004338:Drug Combinations; D016099:Endoscopy, Gastrointestinal; D017809:Fatal Outcome; D005743:Gastrectomy / Q000379:methods*; D006801:Humans; D010535:Laparoscopy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use; D012086:Reoperation; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D005641:Tegafur / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid